Australian Centre for HIV and Hepatitis Virology Research (ACH2)
The Australian Centre for HIV and Hepatitis Virology Research (ACH2) is one of Australia’s four national centres for HIV and Hepatitis research and is funded by the Commonwealth Government as represented by the Department of Health. The purpose of the Centre is to deliver virological and immunological research outcomes of significance to improve the diagnosis, treatment and prevention of HIV and HCV in Australia and in a broader regional and international context.
WHAT IS ACH2?
ACH2 represents a continuum in research from basic virology and immunology, through to clinical and social research. The Centre encourages basic scientists, including virology and immunology researchers in HIV and hepatitis fields to translate biomedical discoveries into health care and biotechnology outcomes, and to support clinical research. The Centre has three major activities: a regular expression of interest funding round for strategic projects; the Immunovirology Research Network (IVRN) for nationwide research specimen collection and redistribution for strategic research; an Annual Scientific Workshop to facilitate research collaborations.
The Centre’s ultimate aim is to generate outcomes that will enable Australia to combat the impact of HIV, HCV and HBV locally and in the SE Asia/Pacific region. To achieve its aims, the Centre has established close relationships with the Australian Centre for Hepatitis Virology (ACHV) the Kirby Institute, and also with the Australian Liver Association.
Furthermore, the Centre operates as a virtual institute with open access to all HIV and hepatitis researchers in Australia.
Due to the ongoing COVID-19 pandemic, there have been delays in the release of data usually reported by the Kirby Institute, in the HIV, viral hepatitis and sexually transmissible infections in Australia: Annual Surveillance Report. Summary data is available on the Kirby Institute’s website.